A Double-Blind, Placebo-Controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2014
At a glance
- Drugs AZD 1981 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 17 Mar 2012 Actual end date changed from Jun 2009 to Jan 2010 as reported by European Clinical Trials Database.
- 17 Mar 2012 Planned number of patients changed from 40 to 55 as reported by European Clinical Trials Database.
- 26 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.